Antibiotics were once considered one of the greatest successes of modern medicine, saving millions of lives and allowing many procedures that we consider commonplace today to become possible, such as common surgeries, cancer treatments and organ transplants.
But today resistance to antibiotics is emerging as one of the biggest healthcare challenges of our time.
It endangers the lives of an increasing number of patients and threatens many of the practices of modern medicine on which we have come to rely.
Every country is affected by this growing crisis, and it is estimated that more than 700,000 people globally die each year as a result of resistant infections caused by bacteria, including 33,000 in Europe alone.
As we face another crisis – the fight against COVID-19 – the need for a strong antibiotic pipeline has been further amplified, highlighting the urgent need for increased public health preparedness.
Allecra is helping to fight this battle by developing a novel antibiotic to address an area of growing antimicrobial resistance where safe and effective alternatives are urgently needed.
Addressing a Major Unmet Need in Overcoming Antibiotic Resistance
Allecra Therapeutics, founded in 2013, is a private, clinical-stage biopharmaceutical company developing novel therapies to combat antibiotic resistance by overcoming emergent resistance mechanisms. Lead product candidate, cefepime/enmetazobactam,has shown superiority over standard of care in patients with complicated urinary tract infections (cUTIs) in a randomized, controlled Phase 3 trial, and the Company is preparing submissions for marketing approval in the U.S. and EU based on these results. The Company has significant patent protection covering proprietary enmetazobactam in major territories.
Allecra’s management team includes:Andreas Kranzusch (Chief Financial Officer); Patrick Velicitat, MD (Chief Medical Officer); Omar Lahlou, PhD (Head, Regulatory Affairs) and Adam Belley, PhD (Head, R&D).
The team is supported by a Supervisory Board with strong industry and investment experience: Bert Tjeenk Willink (Chairman), Iain Buchanan, Henry Chen, Olivier Litzka, Holger Reithinger and Jason Rushton.
Allecra’s investors are:
Andera Partners, BioMedPartners, Delos Capital, EMBL Ventures, Forbion and Xeraya Capital. Allecra’s wholly owned French subsidiary is a beneficiary of financial support from Bpifrance and the Région Alsace.